Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc.

NNASDAQ:XBIO
1.49
USD
-0.17
(-10.24%)
-1.18EPS
6.67MMarket Cap
Mar 25Next Earn

Total Valuation

USD

As of June 30, 2026, Xenetic Biosciences, Inc. carries a market capitalization of 6.67M, placing it among publicly traded companies globally. Its enterprise value stands at 195,206.96, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap6.67M
Enterprise Value195,206.96

Important Dates

Xenetic Biosciences, Inc.'s next confirmed earnings release is scheduled for March 25, 2027.

Earnings Date3/25/2027

Share Statistics

As of June 30, 2026, Xenetic Biosciences, Inc. has 2.29M shares outstanding.

Shares Outstanding2.29M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 1.88, and the price-to-book ratio stands at 1.10.

PS Ratio1.88
PB Ratio1.10
P/TBV Ratio1.10
P/FCF Ratio-2.65
P/OCF Ratio-2.65

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 0.06 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 195,206.96 versus a market cap of 6.67M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.06

Financial Position

As of June 30, 2026, Xenetic Biosciences, Inc. maintains a current ratio of 7.43, meaning it holds 7.4x the short-term assets needed to cover near-term liabilities.

Current Ratio7.43
Quick Ratio7.23

Financial Efficiency

USD

Over the twelve months ended June 30, 2026, Xenetic Biosciences, Inc. posted a negative return on equity (ROE) of -47.05, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -40.17, reflecting losses generated across the asset base. The company generates approximately 1.63M in revenue per employee across its workforce of 2.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-47.05
Return on Assets (ROA)-40.17
Revenue Per Employee1.63M
Employee Count2.00

Stock Price Statistics

USD

As of the close on November 16, 2026, Xenetic Biosciences, Inc.'s stock has declined approximately 42.69% over the past 52 weeks. The 50-day moving average sits at 2.35, while the 200-day moving average is 2.81.

52-Week Price Change-42.69%
50-Day Moving Average2.35
200-Day Moving Average2.81

Income Statement

USD

Over the twelve months ended June 30, 2026, Xenetic Biosciences, Inc. generated 3.26M in revenue and converted that into -2.48M in net income, yielding earnings per share of -1.18. EBITDA reached -2.64M, while operating income came in at -2.64M.

Revenue3.26M
Operating Income-2.64M
Pretax Income-2.48M
Net Income-2.48M
EBITDA-2.64M
EBIT-2.64M
Earnings Per Share (EPS)-1.18

Balance Sheet

USD

These figures are as of June 30, 2026. Total book value stands at 6.07M, with working capital of 5.76M providing operational flexibility.

Cash & Cash Equivalents6.47M
Net Debt-6.47M
Equity (Book Value)6.07M
Book Value Per Share2.65
Working Capital5.76M

Cash Flow

USD

Xenetic Biosciences, Inc. produced -2.31M in operating cash flow over the twelve months ended June 30, 2026.

Operating Cash Flow-2.31M
Free Cash Flow-2.31M
FCF Per Share-1.10

Margins

These figures cover the twelve months ended June 30, 2026. The operating margin of -81.01 and net profit margin of -75.91 provide insight into operational efficiency.

Operating Margin-81.01
Pretax Margin-75.91
Profit Margin-75.91
EBITDA Margin-81.01

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -37.76: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

FCF Yield-37.76

Stock Splits

Xenetic Biosciences, Inc.'s most recent stock split took place on May 15, 2023 with a 10:1 split ratio.

Last Split Date5/15/2023
Split Ratio10:1

Scores

As of June 30, 2026, Xenetic Biosciences, Inc. has an Altman Z-Score of -35.76, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-35.76